Marina Serper, Rachel E. Patzer, Peter P. Reese, Kamila Przytula, Rachel Koval, Daniela P. Ladner, Josh Levitsky, Michael M. Abecassis, Michael S. Wolf – 13 October 2014 – Medication nonadherence after liver transplantation (LT) is associated with adverse clinical outcomes such as graft rejection and graft loss. Few studies have examined nonadherence and its impact on clinical outcomes in LT.
Tetsuji Fujita – 12 October 2014
Qilin Gu, Zongbin Cui – 12 October 2014
Manlio Vinciguerra – 12 October 2014
Yohei Fujii, Yoshihito Uchida, Satoshi Mochida – 12 October 2014
Morris Sherman, Jordi Bruix – 12 October 2014
Yohei Fujii, Yoshihito Uchida, Satoshi Mochida – 12 October 2014
Xiuling Zhi, Ling Lin, Shaoxian Yang, Krithika Bhuvaneshwar, Hongkun Wang, Yuriy Gusev, Mi‐Hye Lee, Bhaskar Kallakury, Narayan Shivapurkar, Katherine Cahn, Xuefei Tian, John L. Marshall, Stephen W. Byers, Aiwu R. He – 12 October 2014 – βII‐Spectrin (SPTBN1) is an adapter protein for Smad3/Smad4 complex formation during transforming growth factor beta (TGF‐β) signal transduction. Forty percent of SPTBN1+/− mice spontaneously develop hepatocellular carcinoma (HCC), and most cases of human HCC have significant reductions in SPTBN1 expression.
Ling Li, Florin M. Selaru – 12 October 2014
Shintaro Kuroda, Hirotaka Tashiro, Yasuhiro Kimura, Kaori Hirata, Misaki Tsutada, Yoshihiro Mikuriya, Tsuyoshi Kobayashi, Hironobu Amano, Yuka Tanaka, Hideki Ohdan – 11 October 2014 – Rho‐kinase (ROCK) inhibitors improve liver blood flow after ischemia/reperfusion (IR) injury, especially in the setting of steatosis, by decreasing the resistance of intrahepatic microcirculation through hepatic stellate cell (HSC) relaxation. However, the systemic administration of ROCK inhibitors causes severe hypotension; therefore, liver‐specific ROCK inhibition is required.